Complications of calcaneo-stop procedure in pediatric flexible flatfoot: a systematic review and meta-analysis.

J Pediatr Orthop BMay 22, 2026 (epub)
Clinical ResearchOrthopedic SurgeryPediatricsOpen access

Vito Pavone, Gianluca Testa, Marco Sapienza et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated complications associated with the calcaneo-stop procedure for treating pediatric flexible flatfoot in patients under 18 years. Analyzing 22 studies with 1777 patients, the overall pooled complication rate was found to be 7.97% (95% CI: 5.96-9.97%).

Key findings

  • The most common complications included postoperative pain (2.79%) and reintervention (2.27%).
  • Complication rates were significantly higher in patients older than 13 years at 15.84% (P < 0.001).
  • Cortical screws had a complication rate of 13.2%, while bioabsorbable screws showed the lowest rates.

Why it matters

Understanding the complication rates associated with the calcaneo-stop procedure can help clinicians make informed decisions regarding treatment options for pediatric flexible flatfoot, particularly considering patient age and implant type.

Source

PubMed · PMID 42166630Free full text on PubMed Central

Published in J Pediatr Orthop B. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.